12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SMT C1100: Phase Ib start

By year end, Summit will begin an open-label, dose-escalation, U.K. Phase Ib trial to evaluate SMT C1100 in 12 DMD patients ages 5-11 years. The trial will use a nanoparticle aqueous suspension reformulation of SMT C11000 that the company previously used in a Phase I trial. Last year, Summit reported data...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >